首页> 外文期刊>Toxicology and Applied Pharmacology >Nrf1 is paved as a new strategic avenue to prevent and treat cancer, neurodegenerative and other diseases
【24h】

Nrf1 is paved as a new strategic avenue to prevent and treat cancer, neurodegenerative and other diseases

机译:NRF1被铺成为新的战略途径,以预防和治疗癌症,神经变性和其他疾病

获取原文
获取原文并翻译 | 示例
           

摘要

Transcription factor Nrf1 acts as a unique vital player in maintaining cellular homeostasis and organ integrity during normal development and growth throughout the life process. Loss-of-function of Nrf1 results in severe oxidative stress, genomic instability, embryonic lethality, developmental disorders, and adult diseases such as non-alcoholic steatohepatitis, hepatocellular carcinoma, diabetes and neurogenerative diseases. Thereby, Nrf1 is critically implicated in a variety of important physio-pathological processes by governing robust target genes in order to reinforce antioxidant, detoxification and cytoprotective responses to cellular stress. Notably, there also exists a proteasomal 'bounce-back' response mediated by Nrf1, insofar as to enhance the drug resistance to proteasomal inhibitors in clinical treatment of neuroblastoma, multiple myeloma and triple-negative breast cancers. Recently, several drugs or chemicals are found or re-found in new ways to block the proteasomal compensatory process through inhibiting the multistep processing of Nrf1. Conversely, activation of Nrf1 induced by some drugs or chemicals leads to cytoprotection from cell apoptosis and promotes cell viability. This is the start of constructive and meaningful studies, approaching to explore the mechanism(s) by which Nrf1 is activated to protect neurons and other cells from malignant and degenerative diseases. Overall, Nrf1 has appealed attentions as a new attractive therapeutic strategy for human diseases including cancers
机译:转录因子NRF1作为在正常发育和生长过程中维持细胞稳态和器官完整性的独特生命球员。 NRF1的失程导致严重的氧化应激,基因组不稳定性,胚胎致死性,发育障碍和成年疾病,如非酒精性脱脂性肝炎,肝细胞癌,糖尿病和神经源性疾病。由此,NRF1通过控制稳健的靶基因,以加强对细胞应激的抗氧化,排毒和细胞保护反应来统治各种重要的物理病理过程。值得注意的是,也存在由NRF1介导的蛋白酶体的“反弹”反应,以提高临床治疗神经母细胞瘤,多发性骨髓瘤和三阴性乳腺癌的临床治疗中对蛋白酶体抑制剂的耐药性。最近,通过抑制NRF1的多步骤处理,以新的方式发现或重新发现几种药物或化学品以阻止蛋白酶体补偿过程。相反,一些药物或化学物质诱导的NRF1的激活导致来自细胞凋亡的细胞保护,并促进细胞活力。这是建设性和有意义的研究的开始,接近探索NRF1被激活以保护神经元和来自恶性和退行性疾病的其他细胞的机制。总体而言,NRF1将注意力呼吁关注作为癌症(包括癌症)的新有吸引力的治疗策略

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号